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Long-term immunity against yellow fever in children 
vaccinated during infancy: a longitudinal cohort study
Cristina Domingo, Juliane Fraissinet, Patrick O Ansah, Corey Kelly, Niranjan Bhat, Samba O Sow, José E Mejía
Summary
Background A single dose of vaccine against yellow fever is routinely administered to infants aged 9–12 months under 
the Expanded Programme on Immunization, but the long-term outcome of vaccination in this age group is unknown. 
We aimed to evaluate the long-term persistence of neutralising antibodies to yellow fever virus following routine 
vaccination in infancy.
Methods We did a longitudinal cohort study, using a microneutralisation assay to measure protective antibodies 
against yellow fever in Malian and Ghanaian children vaccinated around age 9 months and followed up for 4·5 years 
(Mali), or 2·3 and 6·0 years (Ghana). Healthy children with available day-0 sera, a complete follow-up history, and no 
record of yellow fever revaccination were included; children seropositive for yellow fever at baseline were excluded. 
We standardised antibody concentrations with reference to the yellow fever WHO International Standard.
Findings We included 587 Malian and 436 Ghanaian children vaccinated between June 5, 2009, and Dec 26, 2012. In 
the Malian group, 296 (50·4%, 95% CI 46·4–54·5) were seropositive (antibody concentration ≥0·5 IU/mL) 4·5 years 
after vaccination. Among the Ghanaian children, 121 (27·8%, 23·5–32·0) were seropositive after 2·3 years. These 
results show a large decrease from the proportions of seropositive infants 28 days after vaccination, 96·7% in Mali 
and 72·7% in Ghana, reported by a previous study of both study populations. The number of seropositive children 
increased to 188 (43·1%, 95% CI 38·5–47·8) in the Ghanaian group 6·0 years after vaccination, but this result might 
be confounded by unrecorded revaccination or natural infection with wild yellow fever virus during a 2011–12 outbreak 
in northern Ghana.
Interpretation Rapid waning of immunity during the early years after vaccination of 9-month-old infants argues for a 
revision of the single-dose recommendation for this target population in endemic countries. The short duration of 
immunity in many vaccinees suggests that booster vaccination is necessary to meet the 80% population immunity 
threshold for prevention of yellow fever outbreaks.
Funding Wellcome Trust.
Copyright Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the 
CC BY 4.0 license.
Introduction
Yellow fever is a persistent public health problem and a 
growing concern in 34 African countries and 13 countries 
in the Americas.1 The re-emergence of yellow fever has 
led to the largest outbreak in Africa of the past 20 years: 
the Angola outbreak of December, 2015, connected with 
the 2016 outbreak in the neighbouring Democratic 
Republic of the Congo. During the outbreak that started 
in Brazil in 2016, the virus spread into areas that were not 
previously considered at high risk, including the densely 
populated periphery of the large cities of São Paulo, 
Rio de Janeiro, and Salvador de Bahia.
The evolving epidemiology of the disease and the 
expansion of at-risk areas have been associated with 
prolonged periods of increased rainfall and temperatures 
and with environmental perturbations arising from 
human activity (eg, deforestation, population movements, 
and changes in land use).2 The resurgence of yellow fever, 
however, has been attributed largely to lapses of continuous 
vaccination coverage and the waning of population 
immunity in areas of yellow fever trans mission, which 
makes outbreaks more frequent.3 It is estimated that 
393·7–472·9 million people will require vaccination4 to 
achieve the population immunity recommended by WHO 
for countries at risk.1
The vaccines against yellow fever are safe and 
efficacious and consist of live attenuated virus that is 
usually administered by subcutaneous injection. WHO 
guidelines advocate a single dose of vaccine for life-long 
protective immunity against yellow fever.5 In endemic 
countries, the vaccine is routinely given to infants at 
9–12 months of age as part of the Expanded Programme 
on Immunization. The merits of one-dose vaccination 
at such early ages have not yet been supported by 
evidence that shows vaccine-elicited immunity to yellow 
fever persisting for many years in the absence of booster 
doses. Several studies have shown a decrease in 
seropositivity and antibody titres in vaccines over time, 
with 71–82% of adults seropositive 10 years or more 
after vaccination.6 Studies on the loss of immunity in 
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adults done in non-endemic settings, where a boost of 
vaccine-induced immunity by later natural infections 
is unlikely, have reported that up to 30%–40% of 
individuals serorevert 5–10 years after vaccination.6 
Children, however, showed lower sero conversion rates 
and titres than healthy adults and might lose immunity 
faster.7
Longitudinal studies of vaccine immunogenicity are 
essential to determine the risk of vaccination failure in 
individuals and to verify whether the single-dose policy 
guarantees community-level immunity above the 80% 
protective threshold against outbreaks. We evaluated 
the long-term persistence of neutralising antibodies to 
yellow fever virus following routine vaccination in infants 
aged around 9 months.
Methods
Study design and participants
We did a longitudinal cohort study. We studied two groups 
of healthy children: one from Ghana and one from Mali. 
Both groups are subsets of the study populations in trials of 
the meningococcal group A conjugate vaccine, MenAfriVac, 
administered to infants in association with other local 
Expanded Programme on Immunization vaccines, namely 
the PsATT-004 (phase 2, ISRCTN82484612) and Pers-004 
(phase 4, ISRCTN10763234) studies in Ghana and 
the PsATT-007 (phase 3, PACTR201110000328305) and 
Pers-007 (phase 4, ISRCTN37623829) studies in Mali 
(appendix p 2).
The children were concomitantly vaccinated under the 
Expanded Programme on Immunization schedule 
against yellow fever and measles at 8–12 months of age. 
Ghanaian children received the YF-17DD yellow fever 
vaccine strain (Bio-Manguinhos-Fiocruz, Rio de Janeiro, 
Brazil), and Malian children were vaccinated with the 
YF-17D-213 strain (Chumakov Institute of Poliomyelitis 
and Viral Encephalitides of the Russian Academy of 
Sciences, Moscow, Russia). The children provided serum 
samples either around 2·3 and 6·0 years (PsATT-004 and 
Pers-004, Ghana) or 4·5 years (Pers-007, Mali) after 
vaccination (table 1). Only healthy children with available 
Research in context
Evidence before this study
WHO has recommended a single lifetime vaccination against 
yellow fever since 2013, following published evidence 
of long-lasting immunogenicity of the YF-17D vaccine. 
The requirement for a booster dose every 10 years was 
accordingly removed from the International Health Regulations 
in 2016. A shortcoming of this policy change is the scarcity of 
information on the effective duration of protective immunity 
elicited in vaccinated infants, even though this age group 
constitute the main vaccination target in yellow fever-endemic 
countries. We consulted reference documents prepared by WHO 
and by the Centers for Disease Control and Prevention on 
yellow fever vaccination and the primary sources on the 
duration of yellow fever vaccine immunity surveyed from four 
review articles from 2013–16, including one meta-analysis and 
one systematic review. We also searched PubMed on May 18, 
2018, with the expressions “yellow fever immunity” and 
“children” or “infants”, “yellow fever immunity” and 
“persistence”, and “yellow fever vaccine”, and did a reverse 
search on the Web of Science database, for articles citing 
three highly relevant research reports. We did not apply any 
language or date restrictions. Although the yellow fever vaccine 
can elicit lifelong immunity, studies in healthy adults have 
observed a time-dependent decrease in the proportion of 
seropositive individuals to 71–82% 10 years or more after 
vaccination, down from the proportion of more than 
90% usually detected during the first year. Studies in 
non-endemic settings, where interference from circulating 
flaviviruses can be discounted, have reported a 
30–40% decrease in vaccine-induced immunity 5–10 years after 
yellow fever vaccination. Infants, and children in general, 
exhibit a higher vaccine failure and lower immune responses 
after vaccination than adults, but previous studies on the 
outcome of yellow fever vaccination have focused mainly on 
adults or older children. Studies covering vaccinated infants 
have been limited to determining seroconversion 1–3 months 
after vaccination.
Added value of this study
We show a large decline in humoral immunity to yellow fever 
after 2–6 years in each group of children relative to earlier 
observations 4 weeks after vaccination. Proportions of 
seropositive children approximately halved, leaving large 
proportions of the study populations with a negative 
serostatus. These results address an important knowledge gap 
and are informative on the evolution of conferred immunity, 
in two different African settings endemic for yellow fever.
Implications of all the available evidence
Our findings argue for the one-dose-for-life guidelines to be 
reconsidered for individuals who receive yellow fever 
vaccination as infants. The long-term decline of humoral 
immunity suggests that a single dose of the vaccine, 
administered at 9 months of age, might not achieve a 
population immunity protective against yellow fever 
epidemics.
See Online for appendix













Ghana, year 2·3 2·3 733–874 823 (815–830) 36–38 36 (36–36) 3·0 (0·01)
Ghana, year 6·0 6·0 2048–2331 2180 (2142–2219) 77–85 80 (79–82) 6·7 (0·1)
Mali, year 4·5 4·5 1444–1793 1626 (1514–1688) 56–68 62 (59–64) 5·2 (0·3)
Table 1: Schedule of sample collections after yellow fever vaccination
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day-0 sera, a complete follow-up history, and no record of 
yellow fever revaccination were included; children who 
were seropositive for yellow fever at baseline were 
excluded.
The study protocol was approved by the ethics 
committees for studies involving human participants at 
the Navrongo Health Research Centre, Navrongo, Ghana, 
and the National Institute for Research in Public Health, 
Bamako, Mali. All procedures complied with the 
Declaration of Helsinki. Written informed consent was 
provided by the participants’ parents or legal guardians 
in accordance with international ethical guidelines for 
epidemiological studies and with applicable local ethical 
guidance and requirements.
Procedures
Blood samples were obtained by standard venipuncture. 
The measured outcomes were the serum concentration of 
neutralising antibodies to yellow fever virus 4·5 years after 
vaccination (Mali) or 2·3 and 6·0 years after vaccination 
(Ghana) and, in each cohort, the relative proportions 
of seropositive, borderline, and seronegative study 
participants at these timepoints. Titres of neutralising 
antibodies to yellow fever virus were determined by a 
microneutralisation assay. Briefly, 100 50% tissue culture 
infective doses of a yellow fever virus suspension (strain 
YF-17D-204, Stamaril, Sanofi Pasteur, Val de Reuil, France) 
were reacted with serial two-fold dilutions of sera (starting 
at 1:4) before inoculation into Vero cells cultured in 
96-well plates, which were microscopically examined for 
cytopathic effect after 7 days. Baseline samples were tested 
in the same run as the matching post-vaccination sera. 
A neutralisation antibody titre of 1:10 or higher is 
considered a surrogate of protection.8,9 However, to 
facilitate comparisons with antibody data collected by 
others using non-equivalent methods, we converted our 
titres to standardised concentrations in IU/mL by 
including in every assay two standard samples for yellow 
fever neutralising antibodies, which were themselves 
calibrated at 426·82 IU/mL and 106·70 IU/mL with 
reference to the First International Standard for 
yellow fever vaccine (WHO International Standard, 
NISBC 99/616) reconstituted at 143·00 IU/mL. On the 
basis of earlier studies,10–12 we applied a concentration 
threshold to discriminate seropositive (≥0·5 IU/mL) from 
borderline sera (measurable concentrations <0·5 IU/mL). 
Accordingly, we defined seroconversion and seroreversion 
as the crossing of this threshold over time. We classified 
samples as seronegative if they were ineffective at the 
initial dilution in the assay (1:4).
Figure 1: Forest plots of the prevalence of seropositive children
Seropositive participants at the antibody concentration threshold of 0·5 IU/mL or more are shown at the top of the figure, and seropositive and borderline study 
participants are presented at the bottom as a merged category including all participants with a measurable titre. p values test the differences of proportions 
between groups.
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Seropositive participants (antibody concentration ≥0·5 IU/ml)
Mali, year 4·5, n=587
Total 296 (50·4%, 46·4–54·5) 100·0% 1·120 (1·040–1·210) 0·915 (0·702–1·440)
Low tier 242 (41·2%) 81·8% 0·863 (0·826–0·902) 0·882 (0·610–1·210)
High tier 54 (9·2%) 18·2% 3·530 (3·100–4·070) 2·890 (2·420–4·640)
Ghana, year 2·3, N=436
Total 121 (27·8%, 23·5–32·0) 100·0% 1·380 (1·170–1·660) 1·020 (0·721–2·030)
Low tier 90 (20·6%) 74·4% 0·854 (0·792–0·922) 0·765 (0·610–1·210)
High tier 31 (7·1%) 25·6% 5·560 (4·110–7·790) 4·080 (2·890–8·160)
Ghana, year 6·0, n=436
Total 188 (43·1%, 38·5–47·8) 100·0% 1·790 (1·550–2·080) 1·440 (0·854–2·870)
Low tier 110 (25·2%) 58·5% 0·915 (0·856–0·978) 0·911 (0·647–1·210)
High tier 78 (17·9%) 41·5% 4·610 (3·810–5·670) 2·890 (2·350–7·800)
Borderline participants (measurable antibody concentration <0·5 IU/ml)
Mali, year 4·5 113 (19·3%, 16·1–22·4) NA 0·335 (0·318–0·353) 0·361 (0·271–0·453)
Ghana, year 2·3 51 (11·7%, 8·7–14·7) NA 0·359 (0·337–0·382) 0·381 (0·312–0·430)
Ghana, year 6·0 35 (8·0%, 5·5–10·6) NA 0·334 (0·309–0·361) 0·361 (0·302–0·383)
Broadly seropositive participants (all participants with a measurable antibody concentration)
Mali, year 4·5 409 (69·7%, 66·0–73·4) NA 0·801 (0·742–0·865) 0·721 (0·457–1·220)
Ghana, year 2·3 172 (39·4%, 34·9–44·0) NA 0·926 (0·796–1·090) 0·721 (0·455–1·400)
Ghana, year 6·0 223 (51·1%, 46·5–55·8) NA 1·380 (1·190–1·600) 1·170 (0·640–2·360 )
The low and high tiers of seropositive participants are differentiated at the 1·8 IU/ml or more threshold. 
NA=not applicable.
Table 2: Antibody concentration strata for participants with measurable neutralising antibodies
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Statistical analyses
By calculating the bounds of the 95% CI by the 
asymptotic method assuming 50% seropositivity, we 
determined that a sample of 386 vaccinees or more 
would constrain the 95% CI for the percentage of 
seropositive participants to a 5% interval around the 
empirical percentage.
We analysed the two vaccinee samples from Ghana and 
Mali separately. We used χ² tests to compare the 
proportions of boys and girls between two immunogenicity 
strata, Boschloo’s exact unconditional test13 for other 
2 × 2 comparisons between independent groups, and 
McNemar’s test on the proportions for dichotomous 
outcomes (eg, positives and negatives) in paired sera.
We characterised sets of vaccinees by the geometric 
mean, the median, and the IQR of antibody concen-
trations. We used a percentile bootstrap procedure with 
10⁶ replications to compute the 95% CI for the geometric 
mean. We compared two sets of concentrations by either 
an independent-samples permutation test on the 
difference of geometric means or a permutation-based 
sign test for paired data, as applicable. The permutation 
tests involved 999 999 random replications, ensuring 
precision to three decimal digits for the p value near the 
significance threshold, as estimated by the 95% CI for 
the p value.14 Further details on the tests are provided in 
the appendix (p 3).
We did statistical analysis with R (version 3.4.3 and 
version 3.5.3) software. Hypothesis tests were two-sided, 
and the significance threshold was set at α=0·05.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. CD and JEM had full access to all 
the data in the study. The corresponding author had final 
responsibility for the decision to submit for publication.
Results
We included 436 children (226 [52%] boys, 210 [48%] girls) 
from rural communities in northern Ghana who received 
yellow fever vaccination as part of the Expanded 
Programme on Immunization between June 5, 2009, 
and Feb 25, 2010, and 587 children (297 [51%] boys, 
290 [49%] girls) from urban communities in Mali who 
received vaccination between March 6, 2012, and 
Dec 26, 2012. The mean age at which children were 
vaccinated was 9·0 months (SD 0·3) in Ghana and 
9·4 months (0·8) in Mali. The children provided blood 
samples 2·3 and 6·0 years after vaccination in Ghana 
and 4·5 years after vaccination in Mali (table 1).
In the Malian sample, 296 (50·4%; 95% CI 46·4–54·5) of 
587 children were seropositive 4·5 years after vaccination 
(figure 1). Additionally, we classified 113 (19·3%, 95% CI 
16·1–22·4) children as borderline (antibody concentration 
<0·5 IU/mL). When we merged positive and borderline 
strata into a broadly positive category, 409 (69·7%, 95% CI 
66·0–73·4; table 2) were seropositive. This proportion 
presents a substantial drop from the overall number of 
children who seroconverted (290 [96·7%] of 300 children) 
4 weeks after vaccination in data previously reported 
by others for different samples of the same vaccinee 
population.15
121 (27·8%; 95% CI 23·5–32·0) of 436 Ghanaian 
children were seropositive to yellow fever virus 2·3 years 
after vaccination (figure 1). Among the large majority 
below the seropositivity threshold, we classified 
51 (11·7%, 8·7–14·7) as borderline (table 2). Combination 
of the positive and borderline strata resulted in 
172 children (39·4%, 34·9–44; figure 1). As in Mali, the 
proportion of children with broad-sense seropositivity 
was much smaller than the overall proportion observed 
4 weeks after vaccination (611 [72·7%] of 841 children 
tested) in a previous study of the same Ghanaian 
population.15
In summary, despite differences between our Mali and 
Ghana groups, these data show a substantial long-term 
decline in immunity relative to the early outcome of 
vaccination.
We found the prevalence of seropositivity to be greater 
among the Malian children despite the longer follow-up 
Figure 2: Reverse cumulative distribution plots of neutralising antibody values
(A) Raw titres in the plaque reduction seroneutralisation assay for the full study groups. (B) Standardised antibody 
concentrations for broadly seropositive children (ie, seropositive and borderline study participants). The dotted 
line denotes the threshold for strict seropositivity at 0·5 IU/ml.
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time (50·4% [95% CI 46·4–54·5] vs 27·8% [23·5–32·0]; 
figure 1, 2A), but the prevalence after 4 weeks from an 
earlier study15 was also greater in the Malian than in 
the Ghanaian population samples. The distributions 
of measurable antibody concentrations (ie, those of 
broadly seropositive participants) in the Malian and the 
year-2·3 Ghanaian sera were similar, and we recorded 
the same median concentration (0·721 IU/mL), but we 
observed an excess of higher values in the Ghanaian 
relative to the Malian sera (figure 2B; appendix p 4). The 
geometric mean concentration for the seropositive 
stratum was accordingly higher in the Ghanaian group at 
1·38 IU/mL (95% CI 1·17–1·66) versus 1·12 IU/mL 
(95% CI 1·04–1·21) in Mali (p=0·0087; table 2; 
appendix p 5).
The paired samples taken 2·3 and 6·0 years after 
vaccination showed the evolution of immunogenicity in 
the Ghanaian cohort. This group had a larger proportion 
of seropositive individuals 6·0 years after vaccination 
(43·1% [95% CI 38·5–47·8] vs 27·8% [23·5–32·0]; 
figure 1; table 2). Year-6·0 antibody concentrations were 
also higher overall than the Ghana year-2·3 and the Mali 
year-4·5 values (figure 2B; appendix p 4). 94 Ghanaian 
children were serostable over the intervening period, 
representing 77·7% of the year-2·3 positives and 
21·6% of vaccinees (appendix pp 5–6).
By contrast, 27 seropositive children (22·3% of 
seropositive children in year 2·3) seroreverted in the 
year-6·0 data—ie, deteriorated to negative or bordeline 
serostatus. These children had markedly lower year-2·3 
antibody concentrations than the serostable children 
(geometric mean 0·74 IU/mL [95% CI 0·67–0·83] vs 
1·65 IU/mL [1·35–2·05], p=0·0075; appendix pp 5, 7). We 
observed that lower year-2·3 concentrations were 
associated with higher year-6·0 seroreversion frequencies, 
and that study participants with values 1·8 IU/mL or more 
at year 2·3 were seroreversion-free (p<0·0001; appendix 
p 8). We consequently used 1·8 IU/mL as a tentative 
functional threshold to define a low and a high tier of 
seropositives. 27 (30%) of the 90 low-tier year-2·3 
seropositives seroreverted at year 6·0 after vaccination, 
whereas an even larger proportion of year-2·3 borderline 
participants (24 [47%] of 51) deteriorated to negative 
serostatus (figure 3).
94 (29·8%) of the 315 year-2·3 seronegative or border- 
line children seroconverted between the two collection 
campaigns and accounted for 50% of the seropositive 
children in year 6·0 (figure 3; appendix p 7). Negative 
and borderline children seroconverted in the year-6·0 
sample with similar frequencies (30·3% vs 27·0%, 
p=0·73; figure 3; appendix p 7). The proportions of low-
tier and high-tier seropositive children in each group 
were, however, very different, with seroconversions of 
borderline participants markedly skewed toward the low 
tier (p=0·012; figure 3; appendix p 8).
Sex ratios in the immunity strata considered were 
unbiased relative to the source cohort, and we observed 
no differences by sex in antibody values (appendix p 9), 
except among serostable Ghanaian children, for whom 
the geometric mean concentration increased between 
the two follow-up points in boys, from 1·52 IU/mL 
(95% CI 1·15–2·05) to 2·18 IU/mL (95% CI 1·66–2·91; 
p=0·016), but not in girls (appendix pp 6, 10).
Discussion
Since 2013, WHO has recommended a single dose of 
yellow fever vaccine for life-long immunity, and the 
amended International Health Regulations (2005) no 
longer require revaccination every 10 years.5,16 Although it 
followed evidence of long-term immunogenicity,17,18 this 
policy change has been controversial.19–22 The one-dose 
recommendation bypasses the question of the duration 
of protective immunity elicited in infants, the target 
population of immunisation programmes in endemic 
countries.6 Relevant studies have focused on adults or 
older children, but the duration of immunity against 
yellow fever following infant vaccination has been 
studied only over short post-vaccination periods of 
1–3 months.23 The scarcity of long-term studies on 
neutralising antibodies elicited in vaccinated infants has 
Figure 3: Evolution of the Ghanaian cohort
Flow of study participants from a year-2·3 to a year-6·0 antibody concentration stratum. The thickness of the nodes 
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been identified as a knowledge gap in regard to the need 
for booster doses of the yellow fever vaccine.23
Studies have shown a progressive, long-term decrease 
in neutralisation titres in adults vaccinated against yellow 
fever (by 30%–40% within 5–10 years after vaccination),6 
but also that children seroconvert at comparatively lower 
rates and develop weaker antibody titres.17 Waning 
seroprotection is a major determinant of the need for, and 
periodicity of, revaccination, and the population immunity 
achievable with a single dose of vaccine depends on 
the rate of vaccination failure and on the duration of 
conferred immunity. These parameters are important for 
immunisation programmes in endemic areas, where 
protective immunity covering about 80% of the population 
is necessary to prevent outbreaks.1 Forecasts of population 
coverage under the 2017–26 Eliminating Yellow Fever 
Epidemics strategy,24 which implements vaccination in 
infants as part of the Expanded Programme on 
Immunization in endemic countries, suggest that targets 
will not be met if conferred immunity is short-lived.
We have analysed the long-term persistence of 
neutralising antibodies against yellow fever virus among 
two population samples of African children vaccinated 
under the Expanded Programme on Immunization. The 
importance of humoral immunity in protecting against 
yellow fever is well established,6 as is the detection of 
neutralising antibodies (titre ≥1:10) as a surrogate for 
protective immunity. The role of T-cell-dependent 
immunity is uncertain; humoral immunity is known to 
be crucial, but neither the cellular component nor the 
presence of neutralising antibodies alone might be 
sufficient for protective immunity.25
We normalised assay results to a WHO international 
standard for yellow fever neutralising antibodies, 
which makes it possible to compare our data with 
those from other investigations using standardised 
antibody concentrations. Additionally, we conservatively 
introduced a seropositivity cutoff (≥0·5 IU/mL), because 
very low antibody concentrations might straddle the 
sensitivity threshold of the assay and were associated 
with inconsistent protection in previous studies.26,27
Our findings point to a large decline in yellow 
fever immunity in children vaccinated as infants. The 
reduction in seropositivity, especially among the Ghanaian 
group after only 2·3 years, is noteworthy in comparison 
with previously reported seroconversion 28 days after 
vaccination.15 This suggests a rapid waning of immunity 
during the early years after infant vaccination, similar to 
the decline suggested to occur in adults during the first 
5 years6,8 but affecting a greater proportion of individuals 
or, conceivably, with faster kinetics. Additionally, half of 
the Ghanaian borderline participants became seronegative 
at 6·0 years, which suggests that Malian borderline 
participants (38·8% of borderline and seronegative 
participants) were likewise affected by waning immunity 
(eventual seroreversion could not be determined without 
a later follow-up sample).
Antigenic interference between the live-virus vaccines 
against measles and yellow fever co-administered under 
the Expanded Programme on Immunization should be 
considered as an explanation for the drop in immunity. 
In some studies, the immunogenicity of the yellow fever 
vaccine was decreased by co-administration with the 
measles vaccine, either alone28 or as part of the measles, 
mumps, rubella combination.29 In other studies,30,38,39 
however, no interference could be shown. The sharp 
deterioration of immunity to yellow fever in our data 
shows that the effect of infant co-vaccination on the long-
term evolution of immunogenicity needs to be addressed 
specifically.
The differences in seropositivity between the Ghanaian 
and Malian groups might owe less to the respective vaccine 
strains, which are genetically stable,6 than to factors such 
as vaccine dosage and handling,31 ethnic background,32 
nutritional status, a seasonal effect on immunisation,33 
exposure to other flaviviruses, or the immune 
microenvironment.34 A larger proportion of seroconverted 
individuals was determined for different samples from the 
same study populations (96·7% in Mali and 72·7% in 
Ghana) 28 days after vaccination in a previous study.15 
Relative to the seropositivity in that study (at the ≥1:8 titre 
threshold), we noted an approximately two times long-
term decrease in seropositivity for either population. 
Direct comparison, however, is hindered by differences in 
the population samples and study methods and by non-
standardisation of antibody values in that earlier work.
The numerous late seroconversions in the Ghanaian 
year-6·0 data might have arisen from an external cause. 
The spread of a yellow fever outbreak in the Builsa, 
Kassena-Nankana West, and Kintampo South districts of 
Ghana in 2011 overlapped with the catchment area of this 
study and, chronologically, with the dates of the year-2·3 
collection. Additionally, mass vaccination campaigns in 
the affected areas targeted 5·8 million people in early 
2012.35 Vaccine immunity might have been boosted 
by natural yellow fever virus infection, unreported 
revaccination, or both. In this scenario, averted antibody 
decay in some children or new seroconversions in others 
could lead to an overestimation of the seropositivity 
resulting from the vaccine received at 9–12 months of 
age, a common issue in studies of vaccination in endemic 
areas.6 Unreported infection with wild or vaccinal virus 
might also have contributed to the enrichment in high 
antibody concentrations in the Ghanaian relative to the 
Malian seropositive children, and to the observed 
increase in year-6·0 antibody values among serostable 
boys. Although a higher antibody response to yellow 
fever vaccination has been noted previously in male 
individuals, the incidence of yellow fever is also greater in 
male than in female individuals, possibly determined by 
epidemiological and host-intrinsic factors.36 Additionally, 
the seroconversion of the majority of borderline 
participants to the low tier of seropositivity is in line with 
reports of a negative correlation between pre-existing 
Articles
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antibodies against yellow fever and the magnitude of the 
B-cell response on subsequent exposure to the virus.8,34,37
The inability to control for environmental factors that 
might bias the measured response to yellow fever 
vaccination is a limitation of this study. We cannot exclude 
immune activation by unrelated infections or 
immunisations within the time frame of sample collection, 
or an antigenic challenge of memory immunity by other 
cross-reactive, circulating flaviviruses. Additionally, the 
presence of other vaccines, notably against measles, 
prevents the outcome of yellow fever vaccination from 
being assessed in isolation; however, it is unavoidable in a 
study in endemic countries with routine immunisation 
programmes, and the data are useful within this real-life 
context. The absence of two long-term follow-up points in 
Mali matching those of the Ghanaian cohort also limits 
comparisons between the two groups.
Our study shows that the long-term outcome of the 
vaccination of 9-month-old infants against yellow fever is 
unsatisfactory and argues for the one-dose-for-life 
recommendation to be reconsidered for this population 
in endemic countries. The beneficial effect of a booster 
dose has been established in individuals with low or 
negative neutralisation titres,8 but little evidence focuses 
on children. Further studies will be necessary to plan 
an ideal revaccination strategy against yellow fever 
within the wider schedule of childhood immunisations. 
A booster dose of vaccine would help to attain appropriate 
population immunity against yellow fever outbreaks.
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